Pharmaceuticals
Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
MELBOURNE, Australia, Oct. 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended30 September 2024 (Q3 2024). Revenue update, full year guidance reaffirmed * Unaudited to...
2024-10-17 15:54
1543
Cambrex Opens New Stability Storage Facility in Durham, North Carolina
EAST RUTHERFORD, N.J., Oct. 17, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that their stability storage business, Q1 Scientific, has opened a new cGMP facility inDurham, North Carolina, expanding its capacity for envi...
2024-10-17 15:00
1310
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic...
2024-10-17 14:30
2966
IND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved
SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an application for a phase III clinical study (Study ID: KN026-004) of the anti-HER2 bispecific antibody KN026 combine...
2024-10-17 10:15
1690
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabo...
2024-10-17 08:00
3383
Frost & Sullivan grants the 2024 Global Pluripotent stem cell drug R&D Innovation Award to ZEPHYRM BIOTECHNOLOGIES
SHANGHAI, Oct. 16, 2024 /PRNewswire/ -- The 18th The Growth Innovation Leadership (GIL) Council & the 3rd New Investment Conference in 2024 was held in Shanghai from August 28 to 30, 2024. On the evening of August 28, the prestigious 2024 Global and China Awards for Growth, Innovation, and Leaders...
2024-10-16 13:35
1340
Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies
* After 24 weeks of treatment in patients with Type 2 diabetes, the bi-weekly GLP-1 receptor agonist GZR18 injection showed superior efficacy in lowering HbA1c and body weight compared to semaglutide (Ozempic®). * After 16 weeks of treatment in patients with Type 2 diabetes, the once-weekly i...
2024-10-15 19:36
1163
Delegation of International Communication Experts and Foreign Media Outlets Visits Emerging Industry Enterprises in Zhongshan, Guangdong Province
BEIJING, Oct. 11, 2024 /PRNewswire/ -- On October 9, 2024, the delegation of international communication experts and foreign media outlets, themed "The World Comes to Zhongshan" and organized by the CICG Academy of Translation and Interpretation, visited several representative enterprises in Zhon...
2024-10-11 01:07
2334
Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment
MILAN, Oct. 10, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-jae Lee) announced on the 9th that they will present their cutting-edge drug delivery technologies, including the world's first microneedle-based drugs, at 'CPHI Worldwide 2024'—the world's largest phar...
2024-10-10 06:16
1576
New INTREPID Alliance Antiviral Landscape Report Highlights Urgent Need to Bolster R&D Pipeline in Support of Global Pandemic Preparedness Efforts
Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Today, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral tr...
2024-10-09 19:00
1096
The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.
NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody indepe...
2024-10-09 13:38
1516
Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative
* Werfen, a worldwide leader in specialized diagnostics, becomes the first European company to finalize the partnership agreement to join Seegene's technology-sharing initiative * The two companies will co-establish a NewCo in Spain to serve as a strategic hub inEurope, accelerating global ex...
2024-10-08 21:00
1602
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...
2024-10-08 20:30
3071
Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer
PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor One of two EGFR programs being developed with Scorpion Therapeutics CASTRES, France and BOSTON, Oct. 8, 2024 /PRNewswire/ -- Pierre Fabre Laboratories, a glo...
2024-10-08 20:00
1317
Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC
ROCKVILLE, Md. and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that APG-2449, a FAK/ALK...
2024-10-08 10:26
1433
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
SAN FRANCISCO and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...
2024-10-08 08:00
1618
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
MELBOURNE, Australia, Oct. 8, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of68Ga-PSMA-11[1] injection) to select patients for...
2024-10-08 04:00
1606
The U.S. Fish and Wildlife Service Rejects Petition to List Long-Tailed Macaques Under the Endangered Species Act
WASHINGTON, Oct. 8, 2024 /PRNewswire/ -- On October 7, 2024, the U.S. Fish and Wildlife Service ("USFWS" or "the Service") declined to accept a petition filed by People for the Ethical Treatment of Animals (PETA) and other advocacy groups to list long-tailed macaque ("LTM") monkeys (Macaca fascic...
2024-10-08 03:31
1355
GBI Biomanufacturing and Allterum Therapeutics Announce Strategic Collaboration to Manufacture Therapeutic Antibody for Clinical Trials
PLANTATION, Florida and HOUSTON, Texas, Oct. 8, 2024 /PRNewswire/ -- GBI Biomanufacturing, a leading Contract Development and Manufacturing Organization (CDMO), andAllterum Therapeutics, a Fannin-Founded Company, are pleased to announce a manufacturing partnership to advance Allterum's lead candi...
2024-10-08 00:00
1213
NTC Launches Imperial, the new eye drops product line on THE PATIENT'S SIDE
MILAN, Oct. 7, 2024 /PRNewswire/ -- NTC, an international pharmaceutical company headquartered inMilan, Italy, announced today to have embraced a strategic partnership with Silgan Dispensing Systems, a global leading supplier of dispensing solutions in healthcare to commercialize a set of new NTC...
2024-10-07 18:00
1009
Week's Top Stories
Most Reposted
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 292 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
[Picked up by 279 media titles]
2024-11-08 20:11
Most Read
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10154
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7512
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6227
